clarithromycin has been researched along with cabergoline in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nishikawa, N; Nomoto, M; Nomura, T; Yabe, H | 1 |
| Atilgan, R; Başpınar, M; Ilhan, N; Pala, Ş; Yavuzkır, Ş; Yılmaz, M | 1 |
1 review(s) available for clarithromycin and cabergoline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clarithromycin and cabergoline
| Article | Year |
|---|---|
Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cabergoline; Clarithromycin; Dopamine Agonists; Drug Interactions; Ergolines; Female; Humans; Male; Middle Aged; Parkinson Disease | 2006 |
3 other study(ies) available for clarithromycin and cabergoline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
Topics: Animals; Anti-Bacterial Agents; Cabergoline; Chorionic Gonadotropin; Clarithromycin; Disease Models, Animal; Dopamine Agonists; Estradiol; Female; Gonadotropins, Equine; Interleukin-10; Interleukin-1beta; Ovarian Hyperstimulation Syndrome; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2019 |